OK SB661

Define "opioid analgesic drug product" as drugs in the opioid class prescribed to treat moderate to severe pain in immediate or extended release form, and "abuse-deterrent opioid analgesic drug product" as brand or generic opioid products approved by the FDA with abuse-deterrence labeling claims.

Require health plans to provide coverage for abuse-deterrent opioid analgesic drugs as preferred drugs on formularies and preferred drug lists.

Cap cost sharing for abuse-deterrent opioid analgesic drug products at the lowest cost sharing level applied to all prescription drugs and prohibit increases in patient cost sharing or disincentives to prescribers or dispensers to achieve compliance.

Prohibit prior authorization requirements and utilization review measures from requiring patients to first try non-abuse-deterrent opioid products before accessing abuse-deterrent versions.

Allow insurers and health benefit plans to apply prior authorization requirements to abuse-deterrent opioid products only if the same requirements are applied to non-abuse-deterrent versions.

Effective November 1, 2015.